The vascular endothelium in hypertension: Target and promoter?

Hot Topics in Cardiology

Volumn , Issue 15, 2009, Pages 7-16

  Sudano, Isabella ^a   Flammer, Andreas J ^a   Steffel, Jan ^a   Noll, Georg ^a   Lüscher, Thomas F ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

AMLODIPINE; ANGIOTENSIN ANTAGONIST; ANGIOTENSIN RECEPTOR ANTAGONIST; ATENOLOL; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM ANTAGONIST; CANDESARTAN; CAPTOPRIL; CARVEDILOL; CLONIDINE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; ENALAPRIL; HYDROCHLOROTHIAZIDE; IRBESARTAN; ISRADIPINE; LACIDIPINE; LISINOPRIL; LOSARTAN; METHYLDOPA; METOPROLOL; NEBIVOLOL; NIFEDIPINE; PERINDOPRIL; POTASSIUM SPARING DIURETIC AGENT; QUINAPRIL; RAMIPRIL; TELMISARTAN; UNINDEXED DRUG; VALSARTAN;

ANGINA PECTORIS; CLINICAL TRIAL; DRUG MECHANISM; DRUG POTENTIATION; ENDOTHELIUM; HUMAN; HYPERTENSION; INFLAMMATION; NONHUMAN; REVIEW; THROMBOSIS; TREATMENT DURATION; TREATMENT FAILURE; TREATMENT OUTCOME; VASCULAR ENDOTHELIUM; VASODILATATION;

EID: 77953471196     PISSN: 19739621     EISSN: 20360924     Source Type: Book Series    
DOI: None     Document Type: Review

References (119)

1. British Heart Foundation. European cardiovascular disease statistics: 2000 edition. British Heart Foundation, 2000.
2. Burt VL, Whelton P, Roccella EJ, et al. Prevalence of hypertension in the US adult population. Results from the Third National Health and Nutrition Examination Survey, 1988-1991. Hypertension 1995;25(3): 305-313.
3. Hajjar I, Kotchen TA. Trends in prevalence, awareness, treatment, and control of hypertension in the United States, 1988-2000. JAMA 2003;290(2):199-206.
4. Kearney PM, Whelton M, Reynolds K, Whelton PK, He J. Worldwide prevalence of hypertension: a systematic review. J Hypertens 2004; 22(1):11-19. (Pubitemid 38293521)
5. Wolf-Maier K, Cooper RS, Banegas JR, et al. Hypertension prevalence and blood pressure levels in 6 European countries, Canada, and the United States. JAMA 2003;289(18):2363-2369. (Pubitemid 37430168)
6. Wolf-Maier K, Cooper RS, Kramer H, et al. Hypertension treatment and control in five European countries, Canada, and the United States. Hypertension 2004;43(1):10-17. (Pubitemid 38031904)
7. Lewington S, Clarke R, Qizilbash N, Peto R, Collins R. Age-specific relevance of usual blood pressure to vascular mortality: a metaanalysis of individual data for one million adults in 61 prospective studies. Lancet 2002;360(9349):1903-1913. (Pubitemid 35472129)
8. Gasowski J, Fagard RH, Staessen JA, et al. Pulsatile blood pressure component as predictor of mortality in hypertension: a meta-analysis of clinical trial control groups. J Hypertens 2002;20(1):145-151. (Pubitemid 34913414)
9. Staessen JA, Gasowski J, Wang JG, et al. Risks of untreated and treated isolated systolic hypertension in the elderly: meta-analysis of outcome trials. Lancet 2000;355(9207):865-872. (Pubitemid 30137665)
10. Brunner H, Cockcroft JR, Deanfield J, et al. Endothelial function and dysfunction. Part II: Association with cardiovascular risk factors and diseases. A statement by the Working Group on Endothelins and Endothelial Factors of the European Society of Hypertension. J Hypertens 2005;23(2):233-246. (Pubitemid 40279622)
11. Endemann DH, Schiffrin EL. Endothelial dysfunction. J Am Soc Nephrol 2004;15(8):1983-1992.
12. Deanfield JE, Halcox JP, Rabelink TJ. Endothelial function and dysfunction: testing and clinical relevance. Circulation 2007;115(10): 1285-1295. (Pubitemid 46594773)
13. Lerman A, Zeiher AM. Endothelial function: cardiac events. Circulation 2005;111(3):363-368.
14. Perticone F, Ceravolo R, Pujia A, et al. Prognostic significance of endothelial dysfunction in hypertensive patients. Circulation 2001; 104(2):191-196. (Pubitemid 32655837)
15. Muiesan ML, Salvetti M, Paini A, et al. Prognostic role of flowmediated dilatation of the brachial artery in hypertensive patients. J Hypertens 2008;26(8):1612-1618.
16. 2003 European Society of Hypertension-European Society of Cardiology guidelines for the management of arterial hypertension. J Hypertens 2003;21(6):1011-1053. (Pubitemid 36667855)
17. Chobanian AV, Bakris GL, Black HR, et al. Seventh report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. Hypertension 2003;42(6):1206-1252. (Pubitemid 37553153)
18. Turnbull F. Effects of different blood-pressure-lowering regimens on major cardiovascular events: results of prospectively-designed overviews of randomised trials. Lancet 2003;362(9395):1527-1535. (Pubitemid 37410190)
19. Collins R, Peto R, MacMahon S, et al. Blood pressure, stroke, and coronary heart disease. Part 2, Short-term reductions in blood pressure: overview of randomised drug trials in their epidemiological context. Lancet 1990;335(8693):827-838. (Pubitemid 20113741)
20. Lindholm LH, Carlberg B, Samuelsson O. Should beta blockers remain first choice in the treatment of primary hypertension? A metaanalysis. Lancet 2005;366(9496):1545-1553. (Pubitemid 41540112)
21. Taddei S, Virdis A, Mattei P, Arzilli F, Salvetti A. Endotheliumdependent forearm vasodilation is reduced in normotensive subjects with familial history of hypertension. J Cardiovasc Pharmacol 1992;20 (suppl 12):S193-S195. (Pubitemid 23014145)
22. McAllister AS, Atkinson AB, Johnston GD, Hadden DR, Bell PM, McCance DR. Basal nitric oxide production is impaired in offspring of patients with essential hypertension. Clin Sci (Lond) 1999;97(2):141-147. (Pubitemid 29396618)
23. Millgard J, Lind L. Acute hypertension impairs endotheliumdependent vasodilation. Clin Sci (Lond) 1998;94(6):601-607. (Pubitemid 28269059)
24. Lacolley PJ, Lewis SJ, Brody MJ. L-NG-nitro arginine produces an exaggerated hypertension in anesthetized SHR. Eur J Pharmacol 1991;197(2-3):239-240.
25. Lepori M, Sartori C, Trueb L, Owlya R, Nicod P, Scherrer U. Haemodynamic and sympathetic effects of inhibition of nitric oxide synthase by systemic infusion of N(G)-monomethyl-L-arginine into humans are dose dependent. J Hypertens 1998;16(4):519-523. (Pubitemid 28195861)
26. Sartori C, Lepori M, Scherrer U. Interaction between nitric oxide and the cholinergic and sympathetic nervous system in cardiovascular control in humans. Pharmacol Ther 2005;106(2):209-220. (Pubitemid 40603865)
27. Lüscher TF, Vanhoutte P. The endothelium: Modulator of cardiovascular function. Boca Raton, FL: CRC Press; 1990.
28. Spieker LE, Flammer AJ, Lüscher TF. The Vascular endothelium in hypertension. In Moncada S, Higgs A, eds. The vascular endothelium II (Handbook of experimental pharmacology). Vol 176. Berlin Heidelberg New York: Springer; 2006:249-283.
29. Bhagat K, Moss R, Collier J, Vallance P. Endothelial "stunning" following a brief exposure to endotoxin: a mechanism to link infection and infarction? Cardiovasc Res 1996;32(5):822-829. (Pubitemid 26342646)
30. Bhagat K, Vallance P. Inflammatory cytokines impair endotheliumdependent dilatation in human veins in vivo. Circulation 1997;96(9): 3042-3047. (Pubitemid 27500106)
31. Boulanger C, Lüscher TF. Release of endothelin from the porcine aorta. Inhibition of endothelium-derived nitric oxide. J Clin Invest 1990;85(2):587-590. (Pubitemid 20070070)
32. Fichtlscherer S, Rosenberger G, Walter G, Breuer S, Dimmeler S, Zeiher AM. Elevated C-reactive protein levels and impaired endothelial vasoreactivity in patients with coronary artery disease. Circulation 2000;102:1000-1006. (Pubitemid 30657516)
33. Hingorani AD, Cross J, Kharbanda RK, et al. Acute systemic inflammation impairs endothelium-dependent dilatation in humans. Circulation 2000;102:994-999. (Pubitemid 30657515)
34. Ross R. Atherosclerosis: an inflammatory disease. N Engl J Med 1999;340(2):115-126.
35. Furchgott RF, Zawadzki JV. The obligatory role of endothelial cells in the relaxation of arterial smooth muscle by acetylcholine. Nature 1980;288:373-376. (Pubitemid 11169009)
36. Palmer RM, Ferrige AG, Moncada S. Nitric oxide release accounts for the biological activity of endothelium-derived relaxing factor. Nature 1987;327(6122):524-526. (Pubitemid 17085822)
37. Stamler JS, Singel DJ, Loscalzo J. Biochemistry of nitric oxide and its redox-activated forms. Science 1992;258:1898-1902. (Pubitemid 23026727)
38. Palmer RM, Ashton DS, Moncada S. Vascular endothelial cells synthesize nitric oxide from L-arginine. Nature 1988;333(6174):664-666. (Pubitemid 18158439)
39. Palmer RMJ, Rees DD, Ashton DS, Moncada S. L-arginine is the physiological precursor for the formation of nitric oxide in endothelium-dependent relaxation. Biochem Biophys Res Commun 1988;153:1251-1256.
40. Vallance P, Leone A, Calver A, Collier J, Moncada S. Accumulation of an endogenous inhibitor of nitric oxide synthesis in chronic renal failure. Lancet 1992;339(8793):572-575.
41. Anderson EA, Mark AL. Flow-mediated and reflex changes in large peripheral artery tone in humans. Circulation 1989;79(1):93-100. (Pubitemid 19043679)
42. Vallance P, Collier J, Moncada S. Effects of endothelium-derived nitric oxide on peripheral arteriolar tone in man. Lancet 1989;2(8670): 997-1000. (Pubitemid 19257913)
43. Panza JA, Quyyumi AA, Brush JE Jr, Epstein SE. Abnormal endothelium-dependent vascular relaxation in patients with essential hypertension. N Engl J Med 1990;323(1):22-27. (Pubitemid 20209468)
44. Taddei S, Virdis A, Mattei P, et al. Hypertension causes premature aging of endothelial function in humans. Hypertension 1997;29(3):736-743. (Pubitemid 27097978)
45. Taddei S, Virdis A, Mattei P, et al. Aging and endothelial function in normotensive subjects and patients with essential hypertension. Circulation 1995;91(7):1981-1987.
46. Egashira K, Suzuki S, Hirooka Y, et al. Impaired endotheliumdependent vasodilation of large epicardial and resistance coronary arteries in patients with essential hypertension. Different responses to acetylcholine and substance P. Hypertension 1995;25(2):201-206.
47. Treasure CB, Klein JL, Vita JA, et al. Hypertension and left ventricular hypertrophy are associated with impaired endotheliummediated relaxation in human coronary resistance vessels. Circulation 1993;87(1):86-93. (Pubitemid 23019338)
48. Mimran A. Renal endothelial function in humans. Curr Opin Nephrol Hypertens 1998;7(2):149-152.
49. Deanfield J, Donald A, Ferri C, et al. Endothelial function and dysfunction. Part I: Methodological issues for assessment in the different vascular beds: a statement by the Working Group on Endothelin and Endothelial Factors of the European Society of Hypertension. J Hypertens 2005;23(1):7-17. (Pubitemid 40128972)
50. Iiyama K, Nagano M, Yo Y, et al. Impaired endothelial function with essential hypertension assessed by ultrasonography. Am Heart J 1996;132(4):779-782. (Pubitemid 26366976)
51. Calver A, Collier J, Moncada S, Vallance P. Effect of local intraarterial NG-monomethyl-L-arginine in patients with hypertension: the nitric oxide dilator mechanism appears abnormal. J Hypertens 1992;10(9):1025-1031.
52. Forte P, Copland M, Smith LM, Milne E, Sutherland J, Benjamin N. Basal nitric oxide synthesis in essential hypertension. Lancet 1997;349(9055):837-842. (Pubitemid 27129211)
53. Moncada S, Higgs EA. Arachidonate metabolism in blood cells and the vessel wall. Clin Haematol 1986;15(2):273-292. (Pubitemid 16028873)
54. de Nucci G, Gryglewski RJ, Warner TD, Vane JR. Receptormediated release of endothelium-derived relaxing factor and prostacyclin from bovine aortic endothelial cells is coupled. Proc Natl Acad Sci U S A 1988;85(7):2334-2338. (Pubitemid 24315886)
55. Harrington LS, Carrier MJ, Gallagher N, Gilroy D, Garland CJ, Mitchell JA. Elucidation of the temporal relationship between endothelial-derived NO and EDHF in mesenteric vessels. Am J Physiol Heart Circ Physiol 2007;293(3):H1682- H1688. (Pubitemid 47367215)
56. Mitchell JA, de Nucci G, Warner TD, Vane JR. Different patterns of release of endothelium-derived relaxing factor and prostacyclin. Br J Pharmacol 1992;105(2):485-489.
57. Joannides R, Richard V, Haefeli WE, Linder L, Lüscher TF, Thuillez C. Role of basal and stimulated release of nitric oxide in the regulation of radial artery caliber in humans. Hypertension 1995;26(2):327-331.
58. Coleman RA, Smith WL, Narumiya S. International Union of Pharmacology classification of prostanoid receptors: properties, distribution, and structure of the receptors and their subtypes. Pharmacol Rev 1994;46(2):205-229. (Pubitemid 24185151)
59. Halushka PV, Mais DE, Morinelli TA. Thromboxane and prostacyclin receptors. Prog Clin Biol Res 1989;301:21-28.
60. Shimokawa H, Flavahan NA, Lorenz RR, Vanhoutte PM. Prostacyclin releases endothelium-derived relaxing factor and potentiates its action in coronary arteries of the pig. Br J Pharmacol 1988;95(4):1197-1203. (Pubitemid 19001162)
61. Delpy E, Coste H, Gouville AC. Effects of cyclic GMP elevation on isoprenaline-induced increase in cyclic AMP and relaxation in rat aortic smooth muscle: role of phosphodiesterase 3. Br J Pharmacol 1996;119(3):471-478. (Pubitemid 26335308)
62. Taddei S, Ghiadoni L, Virdis A, Buralli S, Salvetti A. Vasodilation to bradykinin is mediated by an ouabain-sensitive pathway as a compensatory mechanism for impaired nitric oxide availability in essential hypertensive patients. Circulation 1999;100(13):1400-1405. (Pubitemid 29451699)
63. Duvall WL. Endothelial dysfunction and antioxidants. Mt Sinai J Med 2005;72(2):71-80.
64. Edwards G, Dora KA, Gardener MJ, Garland CJ, Weston AH. K+ is an endothelium-derived hyperpolarizing factor in rat arteries. Nature 1998;396(6708):269-272. (Pubitemid 28541391)
65. Campbell WB, Falck JR. Arachidonic acid metabolites as endothelium-derived hyperpolarizing factors. Hypertension 2007; 49(3):590-596. (Pubitemid 46263200)
66. Larsen BT, Gutterman DD, Sato A, et al. Hydrogen peroxide inhibits cytochrome p450 epoxygenases: interaction between two endotheliumderived hyperpolarizing factors. Circ Res 2008;102(1):59-67.
67. Taddei S, Versari D, Cipriano A, et al. Identification of a cytochrome P450 2C9-derived endothelium-derived hyperpolarizing factor in essential hypertensive patients. J Am Coll Cardiol 2006;48(3):508-515. (Pubitemid 44093964)
68. Faraci FM, Sobey CG, Chrissobolis S, Lund DD, Heistad DD, Weintraub NL. Arachidonate dilates basilar artery by lipoxygenasedependent mechanism and activation of K(+) channels. Am J Physiol Regul Integr Comp Physiol 2001;281(1):R246-R253. (Pubitemid 32911851)
69. Bolotina VM, Najibi S, Palacino JJ, Pagano PJ, Cohen RA. Nitric oxide directly activates calcium-dependent potassium channels in vascular smooth muscle. Nature 1994;368(6474):850-853. (Pubitemid 24137748)
70. Ellis A, Triggle CR. Endothelium-derived reactive oxygen species: their relationship to endothelium-dependent hyperpolarization and vascular tone. Can J Physiol Pharmacol 2003;81(11):1013-1028. (Pubitemid 38045830)
71. Popp R, Brandes RP, Ott G, Busse R, Fleming I. Dynamic modulation of interendothelial gap junctional communication by 11,12-epoxyeicosatrienoic acid. Circ Res 2002;90(7):800-806. (Pubitemid 34633896)
72. Wei CM, Hu S, Miller VM, Burnett JC Jr. Vascular actions of C-type natriuretic peptide in isolated porcine coronary arteries and coronary vascular smooth muscle cells. Biochem Biophys Res Commun 1994;205(1):765-771. (Pubitemid 24381692)
73. Griffith TM. Endothelium-dependent smooth muscle hyperpolarization: do gap junctions provide a unifying hypothesis? Br J Pharmacol 2004; 141(6):881-903. (Pubitemid 38510072)
74. Griffith TM, Chaytor AT, Edwards DH. The obligatory link: role of gap junctional communication in endothelium-dependent smooth muscle hyperpolarization. Pharmacol Res 2004;49(6):551-564. (Pubitemid 38338665)
75. Takase H, Moreau P, Kung CF, Nava E, Lüscher TF. Antihypertensive therapy prevents endothelial dysfunction in chronic nitric oxide deficiency. Effect of verapamil and trandolapril. Hypertension 1996;27(1):25-31. (Pubitemid 26017676)
76. Vanhoutte PM, Feletou M, Taddei S. Endothelium-dependent contractions in hypertension. Br J Pharmacol 2005;144(4):449-458.
77. Yanagisawa M, Kurihara H, Kimura S, et al. A novel potent vasoconstrictor peptide produced by vascular endothelial cells. Nature 1988;332(6163):411-415. (Pubitemid 18090241)
78. Rubanyi GM, Botelho LH. Endothelins. FASEB J 1991;5(12):2713-2720.
79. Alberts GF, Peifley KA, Johns A, Kleha JF, Winkles JA. Constitutive endothelin-1 overexpression promotes smooth muscle cell proliferation via an external autocrine loop. J Biol Chem 1994;269(13):10112-10118. (Pubitemid 24196630)
80. Zhou MS, Schulman IH, Raij L. Nitric oxide, angiotensin II, and hypertension. Semin Nephrol 2004;24(4):366-378.
81. Ward NC, Croft KD. Hypertension and oxidative stress. Clin Exp Pharmacol Physiol 2006;33(9):872-876.
82. Ward NC, Hodgson JM, Puddey IB, Mori TA, Beilin LJ, Croft KD. Oxidative stress in human hypertension: association with antihypertensive treatment, gender, nutrition, and lifestyle. Free Radic Biol Med 2004;36(2):226-232. (Pubitemid 38117240)
83. McIntyre M, Bohr DF, Dominiczak AF. Endothelial function in hypertension: the role of superoxide anion. Hypertension 1999;34(4 Pt 1):539-545. (Pubitemid 29496430)
84. Landmesser U, Dikalov S, Price SR, et al. Oxidation of tetrahydrobiopterin leads to uncoupling of endothelial cell nitric oxide synthase in hypertension. J Clin Invest 2003;111(8):1201-1209. (Pubitemid 36519937)
85. Landmesser U, Spiekermann S, Preuss C, et al. Angiotensin II induces endothelial xanthine oxidase activation: role for endothelial dysfunction in patients with coronary disease. Arterioscler Thromb Vasc Biol 2007;27(4):943-948. (Pubitemid 46606729)
86. Zalba G, San Jose G, Moreno MU, et al. Oxidative stress in arterial hypertension: role of NAD(P)H oxidase. Hypertension 2001;38(6):1395-1399. (Pubitemid 34033422)
87. Touyz RM, Schiffrin EL. Reactive oxygen species in vascular biology: implications in hypertension. Histochem Cell Biol 2004;122(4): 339-352. (Pubitemid 39506592)
88. Lassegue B, Griendling KK. Reactive oxygen species in hypertension: an update. Am J Hypertens 2004;17(9):852-860. (Pubitemid 39201104)
89. Droge W. Free radicals in the physiological control of cell function. Physiol Rev 2002;82(1):47-95. (Pubitemid 34654215)
90. Zhang C. The role of inflammatory cytokines in endothelial dysfunction. Basic Res Cardiol 2008;103(5):398-406.
91. Steffel J, Lüscher TF, Tanner FC. Tissue factor in cardiovascular diseases: molecular mechanisms and clinical implications. Circulation 2006;113(5):722-731. (Pubitemid 43754336)
92. He M, He X, Xie Q, Chen F, He S. Angiotensin II induces the expression of tissue factor and its mechanism in human monocytes. Thromb Res 2006;117(5):579-590. (Pubitemid 43326145)
93. Soejima H, Ogawa H, Yasue H, et al. Angiotensin-converting enzyme inhibition reduces monocyte chemoattractant protein-1 and tissue factor levels in patients with myocardial infarction. J Am Coll Cardiol 1999;34(4):983-988. (Pubitemid 29500527)
94. Koh KK, Chung WJ, Ahn JY, et al. Angiotensin II type 1 receptor blockers reduce tissue factor activity and plasminogen activator inhibitor type-1 antigen in hypertensive patients: a randomized, doubleblind, placebo-controlled study. Atherosclerosis 2004;177(1):155-160. (Pubitemid 39361150)
95. Panza JA, Quyyumi AA, Callahan TS, Epstein SE. Effect of antihypertensive treatment on endothelium-dependent vascular relaxation in patients with essential hypertension. J Am Coll Cardiol 1993;21(5):1145-1151. (Pubitemid 23106189)
96. Ghiadoni L, Huang Y, Magagna A, Buralli S, Taddei S, Salvetti A. Effect of acute blood pressure reduction on endothelial function in the brachial artery of patients with essential hypertension. J Hypertens 2001;19(3 Pt 2):547-551. (Pubitemid 32280946)
97. Tschudi MR, Criscione L, Novosel D, Pfeiffer K, Lüscher TF. Antihypertensive therapy augments endothelium-dependent relaxations in coronary arteries of spontaneously hypertensive rats. Circulation 1994;89(5):2212-2218. (Pubitemid 24142801)
98. Wenzel RR, Duthiers N, Noll G, Bucher J, Kaufmann U, Lüscher TF. Endothelin and calcium antagonists in the skin microcirculation of patients with coronary artery disease. Circulation 1996;94(3):316-322. (Pubitemid 26266114)
99. Taddei S, Virdis A, Ghiadoni L, Uleri S, Magagna A, Salvetti A. Lacidipine restores endothelium-dependent vasodilation in essential hypertensive patients. Hypertension 1997;30(6):1606-1612. (Pubitemid 27528112)
100. Verhaar MC, Honing ML, van Dam T, et al. Nifedipine improves endothelial function in hypercholesterolemia, independently of an effect on blood pressure or plasma lipids. Cardiovasc Res 1999;42(3): 752-760. (Pubitemid 29298145)
101. ENCORE Investigators. Effect of nifedipine and cerivastatin on coronary endothelial function in patients with coronary artery disease: the ENCORE I study (Evaluation of Nifedipine and Cerivastatin On Recovery of coronary Endothelial function). Circulation 2003;107(3): 422-428. (Pubitemid 36158044)
102. Lüscher TF, Pieper M, Tendera M, et al. Evaluation of Nifedipine on Coronary Enodthelial Function and Plaque Formation in Patients with Coronary Artery Disease - The Encore II Study. Eur Heart J 2009;in press.
103. Sudano I, Virdis A, Taddei S, et al. Chronic treatment with longacting nifedipine reduces vasoconstriction to endothelin-1 in essential hypertension. Hypertension 2007;49(2):285-290. (Pubitemid 46143003)
104. Ghiadoni L, Magagna A, Versari D, et al. Different effect of antihypertensive drugs on conduit artery endothelial function. Hypertension 2003;41(6):1281-1286. (Pubitemid 36706078)
105. Mancini GB, Henry GC, Macaya C, et al. Angiotensin-converting enzyme inhibition with quinapril improves endothelial vasomotor dysfunction in patients with coronary artery disease. The TREND (Trial on Reversing ENdothelial Dysfunction) Study [published erratum appears in Circulation 1996;94:1490]. Circulation 1996;94(3):258-265. (Pubitemid 26266107)
106. Landmesser U, Drexler H. Effect of angiotensin II type 1 receptor antagonism on endothelial function: role of bradykinin and nitric oxide. J Hypertens Suppl 2006;24(1):39-43. (Pubitemid 44336822)
107. Flammer AJ, Hermann F, Wiesli P, et al. Effect of losartan, compared with atenolol, on endothelial function and oxidative stress in patients with type 2 diabetes and hypertension. J Hypertens 2007; 25(4):785-791. (Pubitemid 46398873)
108. Ghiadoni L, Virdis A, Magagna A, Taddei S, Salvetti A. Effect of the angiotensin II type 1 receptor blocker candesartan on endothelial function in patients with essential hypertension. Hypertension 2000; 35(1 Pt 2):501-506. (Pubitemid 30054224)
109. Grassi G, Quarti-Trevano F, Mancia G. Cardioprotective effects of telmisartan in uncomplicated and complicated hypertension. J Renin Angiotensin Aldosterone Syst 2008;9(2):66-74. (Pubitemid 352005738)
110. Yayama K, Okamoto H. Angiotensin II-induced vasodilation via type 2 receptor: role of bradykinin and nitric oxide. Int Immunopharmacol 2008;8(2):312-318.
111. Koh KK, Quon MJ, Lee Y, et al. Additive beneficial cardiovascular and metabolic effects of combination therapy with ramipril and candesartan in hypertensive patients. Eur Heart J 2007;28(12):1440-1447. (Pubitemid 47343820)
112. Cockcroft JR, Chowienczyk PJ, Brett SE, et al. Nebivolol vasodilates human forearm vasculature: evidence for an Larginine/ NO-dependent mechanism. J Pharmacol Exp Ther 1995; 274(3):1067-1071.
113. Bank AJ, Kelly AS, Thelen AM, Kaiser DR, Gonzalez-Campoy JM. Effects of carvedilol versus metoprolol on endothelial function and oxidative stress in patients with type 2 diabetes mellitus. Am J Hypertens 2007;20(7):777-783. (Pubitemid 46936169)
114. Matsuda Y, Akita H, Terashima M, Shiga N, Kanazawa K, Yokoyama M. Carvedilol improves endothelium-dependent dilatation in patients with coronary artery disease. Am Heart J 2000;140(5):753-759. (Pubitemid 30813082)
115. Boulanger CM. Secondary endothelial dysfunction: hypertension and heart failure. J Mol Cell Cardiol 1999;31(1):39-49. (Pubitemid 29078217)
116. Ceriello A. Possible role of oxidative stress in the pathogenesis of hypertension. Diabetes Care 2008;31 (suppl 2):S181-S184.
117. Hermann M, Flammer A, Lüscher TF. Nitric oxide in hypertension. J Clin Hypertens (Greenwich) 2006;8(12 suppl 4):17-29.
118. Taddei S, Virdis A, Ghiadoni L, Salvetti A. Vascular effects of endothelin-1 in essential hypertension: relationship with cyclooxygenase-derived endothelium-dependent contracting factors and nitric oxide. J Cardiovasc Pharmacol 2000;35(4 suppl 2):S37-S40.
119. Taddei S, Virdis A, Ghiadoni L, Sudano I, Salvetti A. Endothelial dysfunction in hypertension. J Cardiovasc Pharmacol 2001;38 (suppl 2):S11-S14.